Literature DB >> 25430880

Inhibition of Vav3 could reverse the drug resistance of gastric cancer cells by downregulating JNK signaling pathway.

B Tan1, Y Li1, Q Zhao1, L Fan1, Y Liu1, D Wang1, X Zhao1.   

Abstract

This study aims to investigate the effect and mechanism of Vav3 on the multidrug resistance of gastric cancer. Fluorescence quantitative RT-PCR and western blot assay were used to detect Vav3 and drug resistance genes in gastric cancer tissues as well as gastric cell lines such as SGC7901, SGC7901/adriamycin (ADR) and GES-1. Besides, Vav3-specific small interfering RNA (Vav3-siRNA) was applied to inhibit Vav3 in SGC7901/ADR, and SRB assay was used to determine chemosensitivity. After that, drug resistance genes and proteins in MAPK and PI3K/AKT signaling pathway were detected after Vav3-siRNA transfection. The results showed that overexpressed Vav3 was found in gastric cancer tissues and SGC7901 and SGC7901/ADR cells. Activity of SGC7901/ADR cells transfected with Vav3-siRNA combined with 5-fluorouracil/oxaliplatin was much lower than that of control groups, and MDR1/P-gp, GST-π and Bcl-2, Bax genes were significantly downregulated in Vav3-siRNA transfection group. AKT, ERK and p38 total protein and their phosphorylation levels showed no significant change in Vav3-siRNA-transfected SGC7901/ADR cells, whereas the ratio of C-Jun phosphorylation levels to total C-Jun protein was significantly downregulated. The results suggested that Vav3 may play a role in drug resistance of gastric cancer by inhibiting drug resistance genes MDR1/P-gp, GST-π and Bcl-2 through regulating the JNK signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25430880     DOI: 10.1038/cgt.2014.59

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  37 in total

Review 1.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

2.  mTORC1 inhibition and ECM-cell adhesion-independent drug resistance via PI3K-AKT and PI3K-RAS-MAPK feedback loops.

Authors:  Karina Galoian; H T Temple; Armen Galoyan
Journal:  Tumour Biol       Date:  2012-01-14

Review 3.  The cell biology of multiple drug resistance.

Authors:  W T Beck
Journal:  Biochem Pharmacol       Date:  1987-09-15       Impact factor: 5.858

4.  Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.

Authors:  A Oloumi; S H MacPhail; P J Johnston; J P Banáth; P L Olive
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

5.  Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction.

Authors:  Vincent Sauzeau; María A Sevilla; Juan V Rivas-Elena; Enrique de Alava; María J Montero; José M López-Novoa; Xosé R Bustelo
Journal:  Nat Med       Date:  2006-06-11       Impact factor: 53.440

Review 6.  MAPK signal pathways in the regulation of cell proliferation in mammalian cells.

Authors:  Wei Zhang; Hui Tu Liu
Journal:  Cell Res       Date:  2002-03       Impact factor: 25.617

7.  The rho exchange factors vav2 and vav3 control a lung metastasis-specific transcriptional program in breast cancer cells.

Authors:  Carmen Citterio; Mauricio Menacho-Márquez; Ramón García-Escudero; Romain M Larive; Olga Barreiro; Francisco Sánchez-Madrid; Jesús M Paramio; Xosé R Bustelo
Journal:  Sci Signal       Date:  2012-10-02       Impact factor: 8.192

Review 8.  DNA damage repair and tolerance: a role in chemotherapeutic drug resistance.

Authors:  M R Salehan; H R Morse
Journal:  Br J Biomed Sci       Date:  2013       Impact factor: 3.829

9.  Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells.

Authors:  Zonglei Mao; Jin Zhou; Junwei Luan; Weihua Sheng; Xiaochun Shen; Xiaoqiang Dong
Journal:  Biomed Pharmacother       Date:  2013-10-18       Impact factor: 6.529

10.  Heterogeneity of COX-2 and multidrug resistance between primary tumors and regional lymph node metastases of gastric cancer.

Authors:  Yong Li; Bi-bo Tan; Li-qiao Fan; Qun Zhao; Yü Liu; Dong Wang
Journal:  Tumori       Date:  2012 Jul-Aug
View more
  5 in total

1.  Transcriptomic changes associated with DKK4 overexpression in pancreatic cancer cells detected by RNA-Seq.

Authors:  Yongsheng Ouyang; Juncheng Pan; Qiang Tai; Jingfang Ju; Huaizhi Wang
Journal:  Tumour Biol       Date:  2016-02-15

2.  GREM2 maintains stem cell-like phenotypes in gastric cancer cells by regulating the JNK signaling pathway.

Authors:  Ao Ran; Lin Guan; Jiani Wang; Ying Wang
Journal:  Cell Cycle       Date:  2019-08-25       Impact factor: 5.173

3.  Biodegradable micelles enhance the antiglioma activity of curcumin in vitro and in vivo.

Authors:  Songping Zheng; Xiang Gao; Xiaoxiao Liu; Ting Yu; Tianying Zheng; Yi Wang; Chao You
Journal:  Int J Nanomedicine       Date:  2016-06-09

4.  Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?

Authors:  Guangzhen Wu; Qinglian Wang; Yingkun Xu; Jianyi Li; Hongge Zhang; Guanghui Qi; Qinghua Xia
Journal:  Cell Death Dis       Date:  2019-05-28       Impact factor: 8.469

5.  LncRNA RP11-138J23.1 Contributes to Gastric Cancer Progression by Interacting With RNA-Binding Protein HuR.

Authors:  Yongcan Xu; Xiang Yu; Jing Xu; Jun Lu; Hao Jiang; Neng Lou; Wei Lu; Jiewei Xu; Guochao Ye; Shunli Dong; Fengqi Nie
Journal:  Front Oncol       Date:  2022-03-22       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.